320 related articles for article (PubMed ID: 23115122)
21. Renoprotective antioxidant effect of alagebrium in experimental diabetes.
Park J; Kwon MK; Huh JY; Choi WJ; Jeong LS; Nagai R; Kim WY; Kim J; Lee GT; Lee HB; Ha H
Nephrol Dial Transplant; 2011 Nov; 26(11):3474-84. PubMed ID: 21478303
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotection by Spirulina platensis protean extract and phycocyanin against iron-induced toxicity in SH-SY5Y neuroblastoma cells.
Bermejo-Bescós P; Piñero-Estrada E; Villar del Fresno AM
Toxicol In Vitro; 2008 Sep; 22(6):1496-502. PubMed ID: 18572379
[TBL] [Abstract][Full Text] [Related]
23. Phycocyanin ameliorates mouse colitis
Guo W; Zeng M; Zhu S; Li S; Qian Y; Wu H
Food Funct; 2022 Mar; 13(6):3294-3307. PubMed ID: 35244658
[TBL] [Abstract][Full Text] [Related]
24. C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19- induced Damage to the Nervous System.
Pentón-Rol G; Marín-Prida J; McCarty MF
Curr Neuropharmacol; 2021; 19(12):2250-2275. PubMed ID: 33829974
[TBL] [Abstract][Full Text] [Related]
25. Phycocyanobilin is the molecule responsible for the nephroprotective action of phycocyanin in acute kidney injury caused by mercury.
Garcia-Pliego E; Franco-Colin M; Rojas-Franco P; Blas-Valdivia V; Serrano-Contreras JI; Pentón-Rol G; Cano-Europa E
Food Funct; 2021 Apr; 12(7):2985-2994. PubMed ID: 33704296
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of phycocyanin on ischemia/reperfusion liver injuries.
Gdara NB; Belgacem A; Khemiri I; Mannai S; Bitri L
Biomed Pharmacother; 2018 Jun; 102():196-202. PubMed ID: 29558716
[TBL] [Abstract][Full Text] [Related]
27. Oral phycocyanobilin may diminish the pathogenicity of activated brain microglia in neurodegenerative disorders.
McCarty MF; Barroso-Aranda J; Contreras F
Med Hypotheses; 2010 Mar; 74(3):601-5. PubMed ID: 19576698
[TBL] [Abstract][Full Text] [Related]
28. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice.
Ikeda Y; Enomoto H; Tajima S; Izawa-Ishizawa Y; Kihira Y; Ishizawa K; Tomita S; Tsuchiya K; Tamaki T
Am J Physiol Renal Physiol; 2013 Apr; 304(7):F1028-36. PubMed ID: 23389454
[TBL] [Abstract][Full Text] [Related]
29. Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.
Barzegar-Fallah A; Alimoradi H; Asadi F; Dehpour AR; Asgari M; Shafiei M
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):361-8. PubMed ID: 25676798
[TBL] [Abstract][Full Text] [Related]
30. HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice.
Nayak BK; Shanmugasundaram K; Friedrichs WE; Cavaglierii RC; Patel M; Barnes J; Block K
Diabetes; 2016 May; 65(5):1387-97. PubMed ID: 26908870
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.
Li Z; Li Y; Overstreet JM; Chung S; Niu A; Fan X; Wang S; Wang Y; Zhang MZ; Harris RC
Diabetes; 2018 Sep; 67(9):1847-1857. PubMed ID: 29959129
[TBL] [Abstract][Full Text] [Related]
32. Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Zhou G; Wang Y; He P; Li D
Biol Pharm Bull; 2013; 36(12):1883-90. PubMed ID: 24432375
[TBL] [Abstract][Full Text] [Related]
33. The Bioactivities of Phycocyanobilin from Spirulina.
Li Y
J Immunol Res; 2022; 2022():4008991. PubMed ID: 35726224
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy.
Putta S; Lanting L; Sun G; Lawson G; Kato M; Natarajan R
J Am Soc Nephrol; 2012 Mar; 23(3):458-69. PubMed ID: 22223877
[TBL] [Abstract][Full Text] [Related]
35. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
[TBL] [Abstract][Full Text] [Related]
36. Elevated levels of renal and circulating Nop-7-associated 2 (NSA2) in rat and mouse models of diabetes, in mesangial cells in vitro and in patients with diabetic nephropathy.
Shahni R; Gnudi L; King A; Jones P; Malik AN
Diabetologia; 2012 Mar; 55(3):825-34. PubMed ID: 22095236
[TBL] [Abstract][Full Text] [Related]
37. Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression.
Miyazawa T; Zeng F; Wang S; Fan X; Cheng H; Yang H; Bian A; Fogo AB; Harris RC
Kidney Int; 2013 Dec; 84(6):1176-88. PubMed ID: 23760291
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus.
Nakhoul FM; Miller-Lotan R; Awad H; Asleh R; Jad K; Nakhoul N; Asaf R; Abu-Saleh N; Levy AP
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F830-8. PubMed ID: 19176700
[TBL] [Abstract][Full Text] [Related]
39. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2010 Feb; 28(2):340-52. PubMed ID: 19864959
[TBL] [Abstract][Full Text] [Related]
40. Chrysin Inhibits Advanced Glycation End Products-Induced Kidney Fibrosis in Renal Mesangial Cells and Diabetic Kidneys.
Lee EJ; Kang MK; Kim DY; Kim YH; Oh H; Kang YH
Nutrients; 2018 Jul; 10(7):. PubMed ID: 29987200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
